Impact of the Enhanced Permeability and Retention (EPR) Effect and Cathepsins Levels on the Activity of Polymer-Drug Conjugates
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of the Enhanced Permeability and Retention (EPR) Effect and Cathepsins Levels on the Activity of Polymer-Drug Conjugates
Authors
Keywords
-
Journal
Polymers
Volume 6, Issue 8, Pages 2186-2220
Publisher
MDPI AG
Online
2014-08-20
DOI
10.3390/polym6082186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
- (2013) Christopher R. Garrett et al. CANCER
- Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
- (2013) Ruth Duncan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
- (2013) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
- (2013) U. Prabhakar et al. CANCER RESEARCH
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
- (2013) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes
- (2013) Shawn Stapleton et al. JOURNAL OF CONTROLLED RELEASE
- Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery
- (2013) Christin P. Hollis et al. JOURNAL OF CONTROLLED RELEASE
- Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
- (2013) Ahmad Awada et al. LANCET ONCOLOGY
- Profilin 1 as a Target for Cathepsin X Activity in Tumor Cells
- (2013) Urša Pečar Fonović et al. PLoS One
- Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis
- (2013) H. Cabral et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
- (2013) S. Eliasof et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors
- (2012) Kohei Sano et al. ACS Nano
- The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
- (2012) Hiroshi Maeda et al. ADVANCED DRUG DELIVERY REVIEWS
- Combined detection of serum matrix metalloproteinase 9, acetyl heparinase and Cathepsin L in diagnosis of ovarian cancer
- (2012) Wei Zhang et al. Chinese Journal of Cancer Research
- The regulation of cysteine cathepsins and cystatins in human gliomas
- (2012) Boris Gole et al. INTERNATIONAL JOURNAL OF CANCER
- Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
- (2012) YAN-JUN ZHONG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Abstract B52: Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors
- (2012) E. A. Sausville et al. MOLECULAR CANCER THERAPEUTICS
- Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting
- (2012) Hiroshi MAEDA PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Cathepsin X in serum from patients with colorectal cancer: relation to prognosis
- (2012) Tjasa Vizin et al. Radiology and Oncology
- Paclitaxel poliglumex for ovarian cancer
- (2011) Vijaya L Galic et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice
- (2011) Aarthi Gopinathan et al. GUT
- Biodegradable star HPMA polymer–drug conjugates: Biodegradability, distribution and anti-tumor efficacy
- (2011) Tomáš Etrych et al. JOURNAL OF CONTROLLED RELEASE
- Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System
- (2011) C. Heneweer et al. JOURNAL OF NUCLEAR MEDICINE
- Nanomedicine(s) under the Microscope
- (2011) Ruth Duncan et al. MOLECULAR PHARMACEUTICS
- Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients
- (2011) QINGYONG CHEN et al. Oncology Letters
- EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy
- (2010) Hiroshi Maeda et al. ADVANCED DRUG DELIVERY REVIEWS
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
- (2010) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-Tumor-Bearing Mice
- (2010) S. Sadekar et al. BIOMACROMOLECULES
- Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guérin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study
- (2010) P.F. Bassi et al. JOURNAL OF UROLOGY
- Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
- (2009) Ruth Duncan ADVANCED DRUG DELIVERY REVIEWS
- PEG conjugates in clinical development or use as anticancer agents: An overview
- (2009) Gianfranco Pasut et al. ADVANCED DRUG DELIVERY REVIEWS
- Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors
- (2009) Akinori Nagamitsu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Competing Mortality in Advanced Head and Neck Cancer
- (2009) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
- (2009) Corey J. Langer et al. Journal of Thoracic Oncology
- Biodistribution of HPMA Copolymer-Aminohexylgeldanamycin-RGDfK Conjugates for Prostate Cancer Drug Delivery
- (2009) Mark P. Borgman et al. MOLECULAR PHARMACEUTICS
- Polymer-drug conjugates: Recent development in clinical oncology
- (2008) Chun Li et al. ADVANCED DRUG DELIVERY REVIEWS
- Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
- (2008) T Lammers et al. BRITISH JOURNAL OF CANCER
- A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
- (2008) L. C. Scott et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors
- (2008) S. A. Veltkamp et al. CLINICAL CANCER RESEARCH
- Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11-Refractory Model
- (2008) P. Sapra et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers
- (2008) László Herszényi et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
- (2008) H. Maeda et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
- (2008) Paul Sabbatini et al. GYNECOLOGIC ONCOLOGY
- Cysteine cathepsins: Cellular roadmap to different functions
- (2007) Klaudia Brix et al. BIOCHIMIE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More